Literature DB >> 9525276

Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by citrus auraptene in rats.

T Tanaka1, K Kawabata, M Kakumoto, K Matsunaga, H Mori, A Murakami, W Kuki, Y Takahashi, H Yonei, K Satoh, A Hara, M Maeda, T Ota, S Odashima, K Koshimizu, H Ohigashi.   

Abstract

The modifying effects of citrus auraptene given during the initiation and post-initiation phases of oral carcinogenesis initiated with 4-nitroquinoline 1-oxide (4-NQO) were investigated in male F344 rats. At 6 weeks of age, animals were divided into experimental and control groups, and fed the diets containing 100 ppm or 500 ppm auraptene. At 7 weeks of age, all animals except those treated with auraptene alone and control groups were given 4-NQO (20 ppm) in the drinking water for 8 weeks to induce tongue carcinoma. Starting 7 days before the 4-NQO exposure, groups of animals were fed the diets containing auraptene (100 and 500 ppm) for 10 weeks and then switched to the basal diet. Starting 1 week after the cessation of 4-NQO exposure, the groups given 4-NQO and a basal diet were switched to the diets mixed with auraptene (100 and 500 ppm), and maintained on these diets for 22 weeks. The other groups consisted of rats fed auraptene alone (500 ppm) or untreated rats. All rats were necropsied at the termination of the study (week 32). The incidences of tongue lesions (neoplasms and preneoplasms), polyamine levels in the tongue tissue and cell proliferation activity estimated by 5-bromodeoxyuridine (BrdU)-labelling index were compared among the groups. In addition, the activities of gluthathione S-transferase (GST) and quinone reductase (QR) in liver and tongue of rats gavaged various doses of auraptene (0, 200, 400 and 800 mg/kg body wt) for 5 days were assayed. Feeding of auraptene at both doses during the initiation phase caused a significant reduction in the frequency of tongue carcinoma (100 ppm auraptene, 91% reduction, P < 0.001; 500 ppm auraptene, 63% reduction, P < 0.05). When fed auraptene after 4-NQO exposure, the frequency of tongue carcinoma was also decreased (100 ppm auraptene, 100% reduction, P < 0.001; 500 ppm auraptene, 74% reduction, P < 0.01). The incidences of tongue severe dysplasia in these groups were significantly smaller than those in carcinogen controls (P < 0.05). There were no pathological alterations in rats treated with 500 ppm auraptene alone or those in an untreated control group. Dietary administration of auraptene significantly decreased BrdU-labelling index and polyamine concentrations in the oral mucosa (P < 0.05). In addition, auraptene administration significantly increased the activities of GST and QR in the liver and tongue. Although dose-dependent effect was not found, citrus auraptene is effective in inhibiting the development of oral neoplasms induced by 4-NQO. Thus, suppression by the initiation-feeding of auraptene might relate to elevation in the phase II enzymes GST and QR of the liver and tongue, and inhibition occurring during the post-initiation might be related to suppression of increased cell proliferation caused by 4-NQO in the oral mucosa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525276     DOI: 10.1093/carcin/19.3.425

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  16 in total

1.  Protective effects of purple carrot extract (Daucus carota) against rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide.

Authors:  Glaucia Resende Soares; Carolina Foot Gomes de Moura; Marcelo Jose Dias Silva; Wagner Vilegas; Aline Boveto Santamarina; Luciana Pellegrini Pisani; Debora Estadella; Daniel Araki Ribeiro
Journal:  Med Oncol       Date:  2018-03-15       Impact factor: 3.064

2.  Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells.

Authors:  Saffiyeh Saboor-Maleki; Fatemeh B Rassouli; Maryam M Matin; Mehrdad Iranshahi
Journal:  Technol Cancer Res Treat       Date:  2016-05-20

3.  Effects of the tropical ginger compound,1'-acetoxychavicol acetate, against tumor promotion in K5.Stat3C transgenic mice.

Authors:  Vinita Batra; Zanobia Syed; Jennifer N Gill; Malari A Coburn; Patrick Adegboyega; John DiGiovanni; J Michael Mathis; Runhua Shi; John L Clifford; Heather E Kleiner-Hancock
Journal:  J Exp Clin Cancer Res       Date:  2012-06-15

4.  Oral carcinogenesis and oral cancer chemoprevention: a review.

Authors:  Takuji Tanaka; Mayu Tanaka; Takahiro Tanaka
Journal:  Patholog Res Int       Date:  2011-05-22

Review 5.  Overcoming multidrug resistance in human cancer cells by natural compounds.

Authors:  Tomohiro Nabekura
Journal:  Toxins (Basel)       Date:  2010-05-28       Impact factor: 4.546

6.  Understanding carcinogenesis for fighting oral cancer.

Authors:  Takuji Tanaka; Rikako Ishigamori
Journal:  J Oncol       Date:  2011-05-12       Impact factor: 4.375

7.  Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats.

Authors:  Prasad Krishnan; Karen J Yan; David Windler; Jesse Tubbs; Robert Grand; Benjamin D L Li; C Marcelo Aldaz; Jerry McLarty; Heather E Kleiner-Hancock
Journal:  BMC Cancer       Date:  2009-07-29       Impact factor: 4.430

8.  The plant coumarins auraptene and lacinartin as potential multifunctional therapeutic agents for treating periodontal disease.

Authors:  Annie Marquis; Salvatore Genovese; Francesco Epifano; Daniel Grenier
Journal:  BMC Complement Altern Med       Date:  2012-06-28       Impact factor: 3.659

9.  Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7.

Authors:  Prasad Krishnan; Heather Kleiner-Hancock
Journal:  Int J Breast Cancer       Date:  2012-12-18

10.  Evaluation of the Effect of Two Systemic Doses of HESA-A on Prevention of Induced Tongue Neoplasm in Rats.

Authors:  Masoumeh Mehdipour; Ali Taghavi Zenouz; Mehran Mesgari Abbasi; Daryoush Mohajeri; Hossein Damghani; Sanaz Helli; Bita Abdollahi
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2013-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.